Award
National Institute of Allergy and Infectious Diseases 5U01AI158460-05
Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab
Recipient
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Award Amount
$1,183,478.00
Ceiling
$1,183,478.00
Awarded
May 12, 2026
Identifier
5U01AI158460-05
NIH awarded a grant to the University of Texas Health Science Center for a clinical trial studying the effects of dupilumab on asthma and allergic rhinitis, focusing on epithelial integrity and inflammation.
Description
This NIH grant supports a mechanistic clinical trial to evaluate the effects of dupilumab on asthma and allergic rhinitis, focusing on epithelial integrity and inflammation. The project involves controlled allergen challenges and mechanistic studies in systemic and nasal compartments. The award is part of the PAR-21-083 funding opportunity, with a project duration from August 18, 2022, to May 31, 2027.